Literature DB >> 2495317

Treatment of reperfusion injury with intracoronary calcium channel antagonists and reduced coronary free calcium concentration in regionally ischemic, reperfused porcine hearts.

H H Klein1, S Pich, S Lindert, K Nebendahl, G Warneke, H Kreuzer.   

Abstract

The effect of intracoronary diltiazem, EGTA (ethylene-bis-(beta-aminomethylether)-N,N'-tetraacetic acid), nifedipine, verapamil and isotonic saline solution as placebo on reperfusion injury was investigated in regionally ischemic, reperfused porcine hearts. The left anterior descending coronary artery was distally occluded for 45 min and was reperfused for 3 days. Intracoronary infusion was started immediately before reperfusion and continued during 45 min of reperfusion. Infarct size was determined as the ratio of infarcted (tetrazolium stain) to ischemic myocardium (dye technique). Regional systolic shortening was assessed by sonomicrometry. Apart from left ventricular end-diastolic pressure before ischemia and during 45 min of reperfusion, global hemodynamic values in the five treatment groups did not differ; in particular, calculated left ventricular oxygen consumption before and during ischemia was equally low. Intracoronary EGTA decreased coronary venous free calcium concentration to about 70% of baseline value. Infarct size was reduced from 76 +/- 10% (control group, n = 8) to 60 +/- 10% (p less than 0.01) by intracoronary diltiazem (n = 8) and to 55 +/- 15% (p less than 0.01) by intracoronary EGTA (n = 8). Insignificant reductions in infarct size were found after treatment with intracoronary verapamil (63 +/- 18%, n = 8) and intracoronary nifedipine (68 +/- 9%, n = 7). Regional systolic shortening of the risk region, which did not differ among the groups before occlusion and during ischemia, recovered to the greatest extent in the EGTA-treated pigs (p less than 0.01 compared with values in the control group). Treatment with intracoronary calcium antagonists resulted in only marginal improvement of systolic shortening.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495317     DOI: 10.1016/0735-1097(89)90317-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Little Evidence for Lethal Reperfusion Injury to Cardiomyocytes.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

2.  Lethal Reperfusion Injury in Regionally Ischemic, Reperfused Porcine Hearts?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

3.  Major contribution of the 3/6/7 class of TRPC channels to myocardial ischemia/reperfusion and cellular hypoxia/reoxygenation injuries.

Authors:  Xiju He; Shoutian Li; Benju Liu; Sebastian Susperreguy; Karina Formoso; Jinghong Yao; Jinsong Kang; Anbing Shi; Lutz Birnbaumer; Yanhong Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-19       Impact factor: 11.205

4.  Acute treatment with vitamin E does not protect the regionally ischemic, reperfused porcine heart.

Authors:  H H Klein; S Pich; K Nebendahl; P Niedmann; P Schuff-Werner
Journal:  Basic Res Cardiol       Date:  1991 Jan-Feb       Impact factor: 17.165

5.  Ultrastructural Evaluation of Postischemic Cell Death (Lethal Reperfusion Injury) in Porcine Hearts.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 6.  Mitochondrial transplantation: applications for pediatric patients with congenital heart disease.

Authors:  Sitaram M Emani; James D McCully
Journal:  Transl Pediatr       Date:  2018-04

7.  Protective effects of andrographis paniculata nees on post-infarction myocardium in experimental dogs.

Authors:  H Y Zhao; W Y Fang
Journal:  J Tongji Med Univ       Date:  1990

8.  Attenuation of ischemia-reperfusion injury by intracoronary chelating agent administration.

Authors:  Donghoon Han; Si-Hyuck Kang; Chang-Hwan Yoon; Tae-Jin Youn; In-Ho Chae
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.